Pancreatic Cancer early detection and staging clinical standards
Precision diagnostics in pancreatic oncology are vital to overcome silent progression and improve surgical resection rates.
​
In clinical oncology, the diagnosis of pancreatic cancer—specifically pancreatic ductal adenocarcinoma (PDAC)—represents one of the most formidable challenges in modern medicine. The primary clinical friction point is not a lack of therapeutic intent, but the anatomical and biological stealth of the disease. Often situated deep within the retroperitoneum, the pancreas remains shielded from routine physical examinations, allowing malignant transformations to proceed undetected until they involve adjacent vascular structures or neural plexuses.
​
The complexity of this malignancy is compounded by a significant symptom overlap with common, benign gastrointestinal conditions. Patients presenting with vague epigastric discomfort, mild dyspepsia, or back pain are frequently treated for gastritis or musculoskeletal strain for months before definitive imaging is ordered. This testing gap creates a critical delay, as the metabolic doubling time of pancreatic tumor cells is notoriously rapid, often transitioning a case from resectable to metastatic within a narrow diagnostic window.
​
This article clarifies the clinical standards required for identifying early-stage pancreatic lesions and the diagnostic logic necessary to separate high-risk indicators from routine GI complaints. We will explore the technical standards of care, including the hierarchy of imaging modalities, the role of germline testing, and a workable patient workflow designed to maximize the probability of surgical intervention—the only current path to long-term survival.
​
Clinical Checkpoints for Early Detection:
- New-Onset Diabetes: Any patient over 50 developing Type 2 Diabetes without a corresponding increase in BMI should undergo pancreatic imaging.
- Trousseau Sign Awareness: Migratory thrombophlebitis serves as a classic paraneoplastic indicator that demands immediate investigation of the pancreas.
- EUS-FNA Priority: Endoscopic Ultrasound with Fine Needle Aspiration remains the gold standard for tissue acquisition in small, suspicious masses.
- Surveillance Thresholds: High-risk individuals (BRCA2+, PALB2+, or Peutz-Jeghers) must follow a biannual alternating MRI/EUS protocol.
​
See more in this category: Oncology & Cancer Care
​
In this article:
- Context snapshot (definition, who it affects, diagnostic evidence)
- Quick guide
- Understanding in clinical practice
- Practical application and steps
- Technical details
- Statistics and clinical scenario reads
- Practical examples
- Common mistakes
- FAQ
- References and next steps
- Normative/Regulatory basis
- Final considerations
​
Last updated: February 13, 2026.
​
Quick definition: Pancreatic cancer is a malignant proliferation of the exocrine or endocrine cells of the pancreas, most commonly manifesting as Pancreatic Ductal Adenocarcinoma (PDAC), noted for its aggressive local invasion and early systemic spread.
​
Who it applies to: Individuals over 65, chronic smokers, those with long-standing chronic pancreatitis, and patients with specific genetic syndromes or a strong family history of the disease.
​
Time, cost, and diagnostic requirements:
- Diagnostic Window: Suspicious symptoms must be triaged to imaging within 7–14 days to preserve resectability.
- Imaging Protocol: Multiphase CT (Pancreas Protocol) is the primary requirement, followed by Endoscopic Ultrasound (EUS) for biopsy.
- Laboratory Baseline: CA 19-9 levels and a full metabolic panel (focusing on bilirubin and alkaline phosphatase) are mandatory.
- Genetic Documentation: Germline testing is now recommended for 100% of diagnosed patients to identify targetable mutations.
​
Key factors that usually decide clinical outcomes:
- Anatomical Localization: Head-of-pancreas tumors often present earlier due to obstructive jaundice, while tail tumors remain silent longer.
- Vascular Involvement: The degree of contact with the Superior Mesenteric Artery (SMA) and Vein (SMV) determines “Borderline Resectable” status.
- Performance Status: The patient’s ECOG score dictates the intensity of neoadjuvant chemotherapy protocols (e.g., FOLFIRINOX).
- Molecular Signature: The presence of KRAS or G12C mutations increasingly guides second-line precision therapies.
​
Quick guide to early pancreatic detection
- Monitor Indirect Signals: Sudden, unexplained weight loss (>10% body weight) and mid-back pain that radiates from the epigastrium are primary triggers for CT imaging.
- Biomarker Limitations: CA 19-9 should not be used as a standalone screening tool; it is a monitoring signal. Note that 10% of the population (Lewis-negative) cannot produce CA 19-9.
- Imaging Hierarchy: If a standard abdominal CT is inconclusive but clinical suspicion remains, escalate to a dedicated Pancreas Protocol CT or MRCP.
- The Jaundice Alert: Dark urine and pale stools indicate biliary obstruction; this is a “Red Flag” requiring immediate EMRCP or EUS.
- Reasonable Practice: Clinicians should maintain a low threshold for imaging in smokers over 55 who present with “atypical” abdominal symptoms.
​
Understanding Pancreatic Cancer in practice
​
In the clinical environment, the standard of care for pancreatic cancer has shifted from a “surgery-first” mentality to a more nuanced, multidisciplinary diagnostic logic. We now understand that even small tumors may possess a significant micrometastatic burden. Therefore, the diagnostic process is not merely about finding a mass, but about assessing the biological aggressiveness and the relationship between the tumor and the vital vascular highways of the abdomen.
​
The pathophysiological barrier to early detection is the “Desmoplastic Reaction.” Pancreatic tumors create a dense, fibrotic stroma around themselves. This stroma acts as a physical shield, increasing interstitial fluid pressure and collapsing local capillaries. This makes it difficult for biomarkers to reach the systemic circulation in high concentrations early on and, later, prevents chemotherapy from penetrating the tumor core effectively. This “stealth” mechanism is why clinical vigilance must be focused on indirect physiological shifts.
​
Evidence-Based Diagnostic Workflow:
- Phase 1: Clinical suspicion based on weight loss, pain, or jaundice.
- Phase 2: High-resolution multiphase CT to determine resectability (TNM staging).
- Phase 3: EUS-FNA for histological confirmation and molecular profiling.
- Phase 4: Multidisciplinary Board review to choose between neoadjuvant therapy or immediate surgery.
​
Regulatory and practical angles that change the outcome
​
Institutional protocols have evolved to emphasize neoadjuvant chemotherapy (treatment before surgery) for borderline resectable cases. This regulatory shift is driven by evidence that shrinking the tumor away from the mesenteric vessels significantly increases “R0 resection” rates (microscopically clear margins). Documentation of the exact degree of vascular contact—measured in degrees of circumference—is now a mandatory technical requirement for radiologists reporting on pancreatic masses.
​
Furthermore, the Standard of Care now includes universal germline testing for all patients. This is not just for family risk assessment; identify mutations like BRCA1, BRCA2, or PALB2 can change the treatment protocol to include platinum-based agents or PARP inhibitors. The clinical logic is that we are no longer treating “pancreas cancer,” but rather a specific molecular profile that happened to originate in the pancreas.
​
Workable paths patients and doctors actually use
​
In real patient cases, the workflow typically follows one of three paths:
​
- The Resectable Path: Tumor is clearly separated from major vessels. Surgery (Whipple or Distal Pancreatectomy) is scheduled, followed by adjuvant chemotherapy.
- The Borderline/Locally Advanced Path: Tumor involves vessels. FOLFIRINOX or Gemcitabine/Abraxane is administered for 4–6 months to “downstage” the tumor prior to a surgical attempt.
- The Metastatic Path: Evidence of spread to the liver or peritoneum. The goal shifts to systemic control and palliative care, focusing on biliary stenting and pain management (Celiac Plexus Block).
​
Each path relies on the accuracy of the initial staging CT. Misdiagnosis at this stage—such as missing a small liver metastasis—can lead to “unnecessary” major surgery, which delays the start of systemic chemotherapy. This is why “diagnostic patience” (ensuring the staging is perfect) is often more critical than “surgical speed.”
​
Practical application of diagnostic steps in real cases
​
Applying the standard of care in a suspected case of pancreatic cancer requires a sequenced, rapid-fire approach. The typical workflow breaks when a patient is sent for a generic “abdominal ultrasound.” Ultrasound is excellent for gallstones but has a low sensitivity for small pancreatic masses, especially in the tail. A clinical starting point must bypass lower-tier tests when strong indicators (like jaundice or unexplained back pain) are present.
​
The following steps represent the clinical benchmark for navigating a suspected diagnosis. This sequence ensures that the medical record is built with enough data to satisfy both surgical requirements and modern oncological precision standards.
​
- Define the starting point: Identify the “entry symptom” (e.g., Courvoisier’s Sign—a palpable, non-tender gallbladder).
- Build the medical record: Order a Comprehensive Metabolic Panel (CMP) and CA 19-9. Document baseline bilirubin and liver enzyme levels.
- Apply the standard of care: Order a Multidetector CT (MDCT) with a specific pancreas protocol (thin-slice, multiple contrast phases).
- Compare initial findings: If CT shows a mass, move directly to Endoscopic Ultrasound (EUS). If CT is negative but suspicion is high, order an MRI with MRCP.
- Document molecular data: Obtain tissue via EUS-FNA. Request IHC staining and send for germline/somatic mutation testing.
- Escalate to specialist: Present the “complete case” (Imaging + Path + Labs) to a high-volume pancreatic center for surgical evaluation.
​
Technical details and relevant updates
​
Technological updates in 2026 have introduced Liquid Biopsies into the surveillance of high-risk patients. By detecting circulating tumor DNA (ctDNA) or methylated DNA markers in the blood, clinicians can occasionally identify molecular signals of malignancy before a mass is visible on a 2mm CT slice. However, this is still an adjunct to imaging, not a replacement. The observation window for ctDNA is currently being refined to reduce false-positive anxiety.
​
Pharmacological standards are also shifting toward “Total Neoadjuvant Therapy” (TNT). Instead of giving some chemo before and some after surgery, the trend is moving toward giving the entire course before the operation. This tests the chemo-sensitivity of the tumor in vivo. If the CA 19-9 levels do not drop during TNT, it signals a biological failure, and surgery may be deferred as it is unlikely to provide a survival benefit.
​
- Resectability Benchmark: Absence of distant metastases and <180° involvement of the SMA.
- CA 19-9 Anchor: A post-treatment level of <35 U/mL is a strong predictor of improved survival.
- Documentation Standard: Every pathology report should record the Lymph Node Ratio (LNR)—the number of positive nodes divided by the total nodes retrieved.
- Emergency Trigger: Acute ascending cholangitis (fever + jaundice + RUQ pain) requires emergency decompression via ERCP within hours.
​
Statistics and clinical scenario reads
​
The following data represents scenario patterns observed in high-volume oncology registries. These metrics are used by physicians to monitor the impact of early screening and neoadjuvant shifts on the local patient population. These are monitoring signals, not final diagnostic conclusions.
​
Tumor Stage Distribution at Initial Presentation
Distant Metastatic (Stage IV): 52% (Often presents with liver/peritoneal spread)
​
Regional Spread (Stage II/III): 28% (Involves nodes or borderline vascular contact)
​
Localized/Resectable (Stage I): 13% (Target of early detection protocols)
​
Unknown/Non-Staged: 7% (Advanced age or comorbid cases)
​
Before/After Clinical Indicator Shifts
- R0 Resection Rate: 35% → 68% (Typical shift after adopting a Neoadjuvant-First protocol for borderline cases).
- Time to Surgery: 14 days → 120 days (Reflects the move toward pre-operative chemotherapy rather than immediate resection).
- 5-Year Survival (Localized): 20% → 44% (Observed in centers utilizing modern triplet chemotherapy and precision staging).
- Diagnostic Accuracy: 72% → 94% (Improvement seen when escalating from Standard CT to EUS-FNA for small lesions).
​
Monitorable Metrics for Clinical Success
- Bilirubin Levels: Target <2.0 mg/dL prior to starting intensive chemotherapy.
- CA 19-9 Velocity: Monitoring the rate of rise (units/month) to signal early recurrence.
- Absolute Neutrophil Count: Must remain >1,500 cells/mm³ to maintain FOLFIRINOX dosing schedules.
- Performance Status (ECOG): Patients dropping from ECOG 1 to ECOG 2 require immediate dose adjustment.
​
Practical examples of Pancreatic Oncology logic
​
Positive Outcome: Targeted Surveillance
A 52-year-old with a family history of pancreatic cancer and a known BRCA2 mutation undergoes annual EUS. A 9mm lesion is found in the head. EUS-FNA confirms Stage I PDAC. After 4 months of FOLFIRINOX, the lesion is resected with 0/15 positive nodes.
Result: Patient is N-negative and R0. Success was driven by the Surveillance Protocol and early tissue acquisition before the tumor reached the mesenteric vessels.
Complication: Symptom Misinterpretation
A 60-year-old heavy smoker presents with mid-back pain. Treated with NSAIDs and physical therapy for 5 months. When jaundice finally develops, a CT shows a 4cm mass encasing the SMA (locally advanced). Neoadjuvant therapy fails to downstage the tumor.
Result: Case is deemed non-resectable. Complication was caused by an unreasonable delay and a failure to recognize back pain as a pancreatic “Red Flag” in a high-risk patient.
​
Common mistakes in Pancreatic Cancer diagnosis
​
Ultrasound Reliance: Relying on abdominal ultrasound to “rule out” cancer; small tumors or those in the tail are frequently obscured by bowel gas.
​
Biomarker Over-confidence: Dismissing symptoms because CA 19-9 is normal; remember that non-secretors will always test low regardless of tumor burden.
​
Treating the Symptom: Treating “new-onset diabetes” in an older patient as a standard metabolic issue without investigating the pancreas as the potential driver.
​
Delayed Stenting: Waiting too long to decompress a blocked bile duct; high bilirubin delays essential chemotherapy and increases the risk of cholangitis.
​
Ignoring Performance Status: Pushing for major surgery in a patient with an ECOG 3 status; the surgical stress often prevents them from ever receiving lifesaving adjuvant chemo.
​
FAQ about Pancreatic Cancer
​
Why is the surgery for pancreatic cancer (Whipple) considered so complex?
The Whipple procedure, or pancreaticoduodenectomy, involves the removal of the head of the pancreas, the duodenum, a portion of the bile duct, and the gallbladder. This is technically demanding because it requires the reconstruction of three separate vital connections: the pancreas to the small intestine, the bile duct to the intestine, and the stomach to the intestine. Because the pancreas sits at a “crossroads” of major blood vessels like the portal vein, surgeons must often perform delicate vascular grafting if the tumor has made slight contact.
The technical success of the surgery is anchored in the negative margin rate (R0) and the number of lymph nodes harvested (minimum 15). Recovery takes weeks, and complications like pancreatic leaks are possible. However, performing this surgery at a high-volume center—defined as more than 20 cases per year—significantly reduces mortality and improves the typical clinical outcome pattern of long-term disease-free survival.
​
Can pancreatic cancer be detected in a standard blood test?
Currently, there is no single “standard” blood test that can definitively diagnose pancreatic cancer in its early stages. The most common biomarker used is CA 19-9, but it is not sensitive enough for general screening; it is elevated in only about 75-80% of cases and can be high in benign conditions like gallstones or pancreatitis. Clinicians use it as a “monitoring anchor” to see if a treatment is working or if a tumor is regrowing after surgery.
However, technical updates in liquid biopsy research are promising. Scientists are working on multi-cancer early detection (MCED) tests that look for circulating tumor DNA. For now, the most reliable “blood signal” for a doctor is actually a sudden rise in blood sugar (diabetes) or a spike in liver enzymes (alkaline phosphatase), which suggests that a tumor may be interfering with normal organ function. These metabolic shifts often precede more obvious symptoms by months.
​
What is the link between “back pain” and the pancreas?
Pancreatic back pain is distinct because the pancreas is a retroperitoneal organ, meaning it sits behind the stomach and rests directly in front of the spine. When a tumor grows, especially in the body or tail of the pancreas, it can invade the celiac plexus—a dense network of nerves. This causes a boring, persistent pain that often starts in the epigastrium (upper stomach) and radiates directly through to the middle or lower back, typically worsening when lying down.
A concrete clinical anchor for this pain is that it is often “position-dependent.” Patients may find temporary relief by leaning forward or curling into a fetal position, which pulls the pancreas slightly away from the nerve plexus. If a patient presents with chronic mid-back pain that does not improve with physical therapy and is accompanied by even minor weight loss, a pancreas-protocol CT is the only standard way to rule out a silent malignancy.
​
How does a “Pancreas Protocol CT” differ from a normal CT scan?
A standard CT scan of the abdomen often uses thicker slices (5mm) and a single phase of intravenous contrast. This is sufficient for seeing large masses but can easily miss a small 1cm pancreatic tumor. A dedicated Pancreas Protocol CT uses thin-slice imaging (sub-millimeter) and captures images during the precise seconds when the pancreas is most heavily infused with blood—known as the “late arterial” or “pancreatic” phase—as well as the “portal venous” phase to check the veins.
This technical precision allows the radiologist to see the distinct “hypoattenuating” mass (where the tumor doesn’t take up contrast) against the brightly enhancing healthy pancreatic tissue. It also provides a 3D map of the SMA and SMV arteries, which is the primary metric physicians monitor to decide if a patient is a candidate for immediate surgery or needs neoadjuvant chemotherapy first to shrink the tumor away from those vessels.
​
Is chronic pancreatitis a guaranteed precursor to cancer?
While chronic pancreatitis is a known risk factor, it is not a “guarantee” of cancer. Chronic inflammation causes repeated injury and repair to the pancreatic ductal cells, which can lead to mutations, particularly in the KRAS gene. Individuals with chronic pancreatitis have a roughly 2-to-3 fold increase in their lifetime risk of developing PDAC. The challenge is that the scarring from pancreatitis (calcifications and ductal irregularities) can look very similar to a small tumor on a CT scan.
The diagnostic logic for these patients involves regular surveillance with Endoscopic Ultrasound (EUS). EUS allows the physician to look “past” the scarring and perform a fine-needle aspiration if a specific area looks more suspicious than the surrounding inflammation. For patients with hereditary pancreatitis, the risk is much higher (up to 40% lifetime risk), requiring a dedicated surveillance window starting as early as age 40.
​
Who should actually be screened for pancreatic cancer?
Universal screening of the general population is currently not recommended because the disease is relatively rare and the tests are invasive or expensive. However, screening is mandatory for High-Risk Individuals. This includes anyone with two or more first-degree relatives with pancreatic cancer, or those with genetic mutations like BRCA1, BRCA2, PALB2, or ATM, provided they have at least one affected family member. Patients with Peutz-Jeghers syndrome or FAMMM syndrome (p16 mutation) are at the highest risk.
The typical clinical outcome pattern for screened individuals is significantly better than for those diagnosed via symptoms. For these high-risk groups, the protocol usually starts at age 50 (or 10 years earlier than the youngest affected relative). They undergo an annual MRI/MRCP alternating with an EUS. The goal is to catch the disease at the “PanIN” (pre-cancerous) stage or when the tumor is less than 1cm and 100% resectable.
​
What does “borderline resectable” mean for a patient?
A diagnosis of “borderline resectable” means the tumor is technically touching one of the major blood vessels (like the Superior Mesenteric Vein or Artery) but has not completely encased it. In the past, these patients were often denied surgery. Today, the standard of care is to use “neoadjuvant therapy”—usually 4 to 6 months of intensive chemotherapy like FOLFIRINOX—to pull the tumor away from the vessel and kill any invisible microscopic cancer cells that may have escaped into the blood.
The success of this path is monitored by a follow-up CT and a drop in CA 19-9 levels. If the tumor shrinks or remains stable without growing further around the vessel, the patient proceeds to surgery. This “chemo-first” strategy ensures that only patients with favorable biology undergo the major Whipple procedure, as those whose cancer spreads during chemo would not have been cured by surgery anyway.
​
How does a stent help if I have a pancreatic tumor?
When a tumor is located in the head of the pancreas, it often squeezes the common bile duct shut. This causes bile (bilirubin) to back up into the blood, leading to jaundice, severe itching, and liver dysfunction. A stent is a small plastic or metal mesh tube placed during an ERCP procedure to hold the duct open. This is a critical technical step because high bilirubin levels are toxic to the liver and can prevent the patient from being healthy enough to start life-saving chemotherapy.
There are two clinical timing windows for stents: palliative and pre-operative. In palliative cases, a permanent metal stent is used to ensure the patient remains comfortable and jaundice-free. In patients headed for surgery, some surgeons prefer short-term plastic stents or even avoiding stenting if surgery is imminent, to reduce the risk of biliary tract infections (cholangitis) which can complicate the upcoming resection.
​
Are there any new targeted therapies for pancreatic cancer?
Yes, the pharmacological landscape for pancreatic cancer has expanded significantly through precision medicine. For patients with a BRCA1 or BRCA2 mutation, PARP inhibitors like Olaparib can be used as “maintenance therapy” after initial chemotherapy to prevent the cancer from returning. Additionally, tumors that express the KRAS G12C mutation—found in about 1-2% of cases—can now be targeted with specific inhibitors. We also look for “NTRK fusions,” which, though rare, can be treated with highly effective oral drugs.
To access these therapies, the diagnostic logic must include Next-Generation Sequencing (NGS) of the tumor tissue. This molecular profile acts as a blueprint. Even in the metastatic setting, identifying a targetable mutation can transition a patient from a standard “one-size-fits-all” chemotherapy to a personalized regimen that can extend life significantly with fewer side effects than traditional cytotoxic drugs.
​
What can I do to reduce my risk of pancreatic cancer?
While some factors like age and genetics are fixed, lifestyle changes can significantly lower the biological triggers of the disease. Smoking cessation is the most impactful action, as tobacco use is linked to about 25% of all pancreatic cancer cases. Maintaining a healthy weight and controlling blood sugar is also critical, as obesity and Type 2 Diabetes create a state of chronic hyperinsulinemia and inflammation that can promote the formation of “PanIN” lesions in the pancreatic ducts.
Dietary patterns matter as well; a diet high in red and processed meats and low in fruits and vegetables is associated with an increased risk. Clinicians emphasize limiting alcohol intake to prevent chronic pancreatitis, which is a major inflammatory precursor. If you have a strong family history, the most important preventative step is to consult a genetic counselor to determine if you qualify for a high-risk surveillance window.
​
References and next steps
- Genomic Action: If diagnosed, ensure your oncologist orders Germline Genetic Testing within the first 30 days.
- Resectability Review: Request a second opinion from a National Cancer Institute (NCI)-designated center if you are told your tumor is “inoperable” based on vascular contact.
- Symptom Audit: If you are over 50 and develop atypical diabetes (without weight gain), schedule a Pancreas-Protocol CT immediately.
- Clinical Consultation: Engage a multidisciplinary team including a surgical oncologist, medical oncologist, and interventional gastroenterologist.
​
Related reading:
- Understanding the Whipple Procedure: Recovery and Nutrition
- The Role of ctDNA in Early Cancer Detection Protocols
- FOLFIRINOX vs. Gemcitabine: Navigating Chemotherapy Choices
- Genetic Mutations in PDAC: BRCA, PALB2, and ATM explained
- Managing Malabsorption: Pancreatic Enzyme Replacement Therapy (PERT)
- Surveillance Guidelines for High-Risk Pancreatic Families
​
Normative and regulatory basis
The management of pancreatic cancer is governed by evidence-based clinical practice guidelines provided by the National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO). These protocols establish the criteria for resectability and mandate that all patients be considered for clinical trials as part of the first-line standard of care. These standards ensure that diagnostic logic remains consistent across different hospital systems and jurisdictions.
​
Furthermore, regulatory standards emphasize the importance of volume-based outcomes. Institutional protocols often require that complex pancreatic surgeries only be performed at centers that meet specific annual case-load benchmarks to ensure patient safety. Legal and medical standards of care are increasingly driven by the adherence to these “high-volume” surgical and oncological pathways, which have been technically proven to reduce morbidity.
​
Authority Citations:
- National Cancer Institute (NCI): https://www.cancer.gov/types/pancreatic
- Pancreatic Cancer Action Network (PanCAN): https://pancan.org
​
Final considerations
Pancreatic cancer remains a profound clinical challenge, but the paradigm is shifting from fatalism to aggressive precision management. The critical nature of early detection cannot be overstated; it is the difference between a 13% survival rate and a 44% survival rate for localized disease. By identifying the silent signals—atypical diabetes, unexplained back pain, or genetic risk—clinicians can move patients into the surgical window where a cure is possible.
​
The future of pancreatic oncology lies in the integration of liquid biopsies, neoadjuvant triplet chemotherapy, and molecularly targeted agents. While the anatomy of the pancreas remains difficult to access, our diagnostic logic has become more transparent. Success in this field is achieved through vigilant monitoring, rapid triage to high-resolution imaging, and a multidisciplinary commitment to treating the unique biology of every tumor. Vigilance today is the cornerstone of the survival statistics of tomorrow.
​
Diagnostic Urgency: Treat jaundice or new-onset diabetes in older adults as an oncological emergency until proven otherwise by CT.
Biological Priority: Use neoadjuvant therapy for borderline cases to maximize R0 resection probability and assess tumor biology.
Precision Standard: Universal germline testing is mandatory to unlock targetable pathways and protect high-risk family members.
​
- Monitor CA 19-9 velocity as a primary indicator of therapeutic response or early recurrence.
- Prioritize EUS-FNA as the definitive technical standard for small mass tissue acquisition.
- Adhere to NCCN guidelines regarding the use of High-Resolution Pancreas Protocol CT for initial staging.
​
This content is for informational and educational purposes only and does not substitute for individualized medical evaluation, diagnosis, or consultation by a licensed physician or qualified health professional.
